Cholesterol Biosynthesis: A Mechanistic Overview.
暂无分享,去创建一个
P. Fernandes | M. Ramos | D. Gesto | N. M. Cerqueira | Diogo Santos-Martins | H. Moorthy | Eduardo F T Oliveira | Cátia Moreira | Prof. P. A. Fernandes
[1] Malte Kelm,et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. , 2015, Annals of internal medicine.
[2] Improve-It Investigators. Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .
[3] C. Zeng,et al. Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials , 2015, Journal of the American Heart Association.
[4] G. Ness. Physiological feedback regulation of cholesterol biosynthesis: Role of translational control of hepatic HMG-CoA reductase and possible involvement of oxylanosterols. , 2015, Biochimica et biophysica acta.
[5] C. Wilcox,et al. Systematic review: the management of chronic diarrhoea due to bile acid malabsorption , 2014, Alimentary Pharmacology and Therapeutics.
[6] P. Fernandes,et al. Discovery of new druggable sites in the anti-cholesterol target HMG-CoA reductase by computational alanine scanning mutagenesis , 2014, Journal of Molecular Modeling.
[7] P. Fernandes,et al. PLP undergoes conformational changes during the course of an enzymatic reaction. , 2014, Acta crystallographica. Section D, Biological crystallography.
[8] O. Wiest,et al. The increasingly complex mechanism of HMG-CoA reductase. , 2013, Accounts of chemical research.
[9] A. Berghuis,et al. Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition. , 2013, Journal of medicinal chemistry.
[10] M. Murthy,et al. Crystal structures of SCP2-thiolases of Trypanosomatidae, human pathogens causing widespread tropical diseases: the importance for catalysis of the cysteine of the unique HDCF loop. , 2013, The Biochemical journal.
[11] N. Haginoya,et al. Discovery of DF-461, a Potent Squalene Synthase Inhibitor. , 2013, ACS medicinal chemistry letters.
[12] A. Mazein,et al. A comprehensive machine-readable view of the mammalian cholesterol biosynthesis pathway , 2013, Biochemical pharmacology.
[13] P. Fernandes,et al. Unraveling the enigmatic mechanism of L-asparaginase II with QM/QM calculations. , 2013, Journal of the American Chemical Society.
[14] C. Murray,et al. Effect of HMG‐CoA reductase inhibitors on antimicrobial susceptibilities for Gram‐Negative rods , 2013, Journal of basic microbiology.
[15] L. Eriksson,et al. Catalytic mechanism and product specificity of oxidosqualene-lanosterol cyclase: a QM/MM study. , 2012, The journal of physical chemistry. B.
[16] Pedro Alexandrino Fernandes,et al. Computational enzymatic catalysis--clarifying enzymatic mechanisms with the help of computers. , 2012, Physical chemistry chemical physics : PCCP.
[17] William J. McWhorter,et al. Structural basis for nucleotide binding and reaction catalysis in mevalonate diphosphate decarboxylase. , 2012, Biochemistry.
[18] Oliver Nussbaumer,et al. Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents , 2012, Clinical Cancer Research.
[19] Leszek Rychlewski,et al. Squalene monooxygenase – a target for hypercholesterolemic therapy , 2011, Biological chemistry.
[20] P. Fernandes,et al. Mechanism of formation of the internal aldimine in pyridoxal 5'-phosphate-dependent enzymes. , 2011, Journal of the American Chemical Society.
[21] K. Horstman,et al. The paradox of public health genomics: Definition and diagnosis of familial hypercholesterolaemia in three European countries , 2011, Scandinavian journal of public health.
[22] R. Russell,et al. Bisphosphonates: the first 40 years. , 2011, Bone.
[23] William J. McWhorter,et al. Crystal Structures of Staphylococcus epidermidis Mevalonate Diphosphate Decarboxylase Bound to Inhibitory Analogs Reveal New Insight into Substrate Binding and Catalysis* , 2011, The Journal of Biological Chemistry.
[24] P. Fernandes,et al. Computational Mechanistic Studies Addressed to the Transimination Reaction Present in All Pyridoxal 5'-Phosphate-Requiring Enzymes. , 2011, Journal of chemical theory and computation.
[25] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.
[26] E. Oldfield,et al. Mechanism of action and inhibition of dehydrosqualene synthase , 2010, Proceedings of the National Academy of Sciences.
[27] P. Clézardin,et al. How do bisphosphonates inhibit bone metastasis in vivo? , 2010, Neoplasia.
[28] W. Yue,et al. Crystal structures of human HMG-CoA synthase isoforms provide insights into inherited ketogenesis disorders and inhibitor design. , 2010, Journal of molecular biology.
[29] J. Pelkonen,et al. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. , 2009, Bone.
[30] R. Wierenga,et al. The thiolase reaction mechanism: the importance of Asn316 and His348 for stabilizing the enolate intermediate of the Claisen condensation. , 2009, Biochemistry.
[31] J. Medina-Franco,et al. Inhibitors of HMG-CoA Reductase: Current and Future Prospects. , 2009, Mini reviews in medicinal chemistry.
[32] J. Urbina,et al. Ergosterol biosynthesis and drug development for Chagas disease. , 2009, Memorias do Instituto Oswaldo Cruz.
[33] Supa Hannongbua,et al. Substrate induced structural and dynamics changes in human phosphomevalonate kinase and implications for mechanism , 2009, Proteins.
[34] Gordon H Guyatt,et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis , 2009, BMJ : British Medical Journal.
[35] D. Gaudet,et al. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway , 2009, Clinical genetics.
[36] H. Miziorko,et al. Human mevalonate diphosphate decarboxylase: characterization, investigation of the mevalonate diphosphate binding site, and crystal structure. , 2008, Archives of biochemistry and biophysics.
[37] J. Lillehaug,et al. The protein acetyltransferase ARD1: a novel cancer drug target? , 2008, Current cancer drug targets.
[38] Cheng-Hsiang Chang,et al. Importance of Saccharomyces cerevisiae oxidosqualene-lanosterol cyclase tyrosine 707 residue for chair-boat bicyclic ring formation and deprotonation reactions. , 2008, Organic letters.
[39] D. Liang,et al. Crystal structure of human phosphomavelonate kinase at 1.8 Å resolution , 2008, Proteins.
[40] D. Nalin. Comment on: unexpected antimicrobial effect of statins. , 2008, The Journal of antimicrobial chemotherapy.
[41] P. Fernandes,et al. Computational enzymatic catalysis. , 2008, Accounts of chemical research.
[42] V. Nizet,et al. A Cholesterol Biosynthesis Inhibitor Blocks Staphylococcus aureus Virulence , 2008, Science.
[43] H. Miziorko,et al. Biochemical and structural basis for feedback inhibition of mevalonate kinase and isoprenoid metabolism. , 2008, Biochemistry.
[44] J. Cohen,et al. Unexpected antimicrobial effect of statins. , 2007, The Journal of antimicrobial chemotherapy.
[45] H. Miziorko,et al. Functional evaluation of conserved basic residues in human phosphomevalonate kinase. , 2007, Biochemistry.
[46] Chiaki Nakano,et al. Sterol Biosynthesis by a Prokaryote: First in Vitro Identification of the Genes Encoding Squalene Epoxidase and Lanosterol Synthase from Methylococcus capsulatus , 2007, Bioscience, biotechnology, and biochemistry.
[47] Henri Brunengraber,et al. Localization of the pre-squalene segment of the isoprenoid biosynthetic pathway in mammalian peroxisomes , 2007, Histochemistry and Cell Biology.
[48] R. Coleman. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.
[49] A. Turjanski,et al. Investigation of the catalytic mechanism of farnesyl pyrophosphate synthase by computer simulation. , 2006, The journal of physical chemistry. B.
[50] J. Noel,et al. Structural basis for the design of potent and species-specific inhibitors of 3-hydroxy-3-methylglutaryl CoA synthases. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[51] G. Ness,et al. Selective Compensatory Induction of Hepatic HMG-CoA Reductase in Response to Inhibition of Cholesterol Absorption , 2006, Experimental biology and medicine.
[52] H. Miziorko,et al. Phosphomevalonate kinase: functional investigation of the recombinant human enzyme. , 2006, Biochemistry.
[53] I. Hassinen,et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen‐containing bisphosphonates , 2006, British journal of pharmacology.
[54] H. Miziorko,et al. Investigation of the functional contributions of invariant serine residues in yeast mevalonate diphosphate decarboxylase. , 2005, Biochemistry.
[55] B. Bahnson. An atomic-resolution mechanism of 3-hydroxy-3-methylglutaryl-CoA synthase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[56] D. Harrison,et al. 3-hydroxy-3-methylglutaryl-CoA synthase intermediate complex observed in "real-time". , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[57] T. Schulz-Gasch,et al. Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase , 2004, Nature.
[58] V. Rodwell,et al. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases , 2004, Genome Biology.
[59] H. Miziorko,et al. Identification of active site residues in mevalonate diphosphate decarboxylase: Implications for a family of phosphotransferases , 2004, Protein science : a publication of the Protein Society.
[60] J. Concepción,et al. In Vitro and In Vivo Activities of E5700 and ER-119884, Two Novel Orally Active Squalene Synthase Inhibitors, against Trypanosoma cruzi , 2004, Antimicrobial Agents and Chemotherapy.
[61] Ronald J A Wanders,et al. Phosphomevalonate kinase is a cytosolic protein in humans Published, JLR Papers in Press, January 16, 2004. DOI 10.1194/jlr.M300373-JLR200 , 2004, Journal of Lipid Research.
[62] D. Hosfield,et al. Structural Basis for Bisphosphonate-mediated Inhibition of Isoprenoid Biosynthesis* , 2004, Journal of Biological Chemistry.
[63] R. Thoma,et al. The monotopic membrane protein human oxidosqualene cyclase is active as monomer. , 2004, Biochemical and biophysical research communications.
[64] H. Waterham,et al. Human mevalonate pyrophosphate decarboxylase is localized in the cytosol. , 2004, Molecular genetics and metabolism.
[65] Ronald J A Wanders,et al. Mevalonate kinase is a cytosolic enzyme in humans , 2004, Journal of Cell Science.
[66] Detlef D. Leipe,et al. Evolution and classification of P-loop kinases and related proteins. , 2003, Journal of molecular biology.
[67] J. Tobert,et al. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors , 2003, Nature Reviews Drug Discovery.
[68] S. Steinbacher,et al. Crystal structure of the type II isopentenyl diphosphate:dimethylallyl diphosphate isomerase from Bacillus subtilis. , 2003, Journal of molecular biology.
[69] E. Oldfield,et al. Structure and mechanism of action of isopentenylpyrophosphate-dimethylallylpyrophosphate isomerase. , 2003, Journal of the American Chemical Society.
[70] P. Libby. Inflammation in atherosclerosis , 2002, Nature.
[71] J. Concepción,et al. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. , 2002, Molecular and biochemical parasitology.
[72] S. Krisans,et al. Central role of peroxisomes in isoprenoid biosynthesis. , 2002, Progress in lipid research.
[73] B. A. Hess,et al. Concomitant C-ring Expansion and D-ring formation in lanosterol biosynthesis from squalene without violation of Markovnikov's rule. , 2002, Journal of the American Chemical Society.
[74] Autumn L. Sutherlin,et al. Enterococcus faecalis 3-Hydroxy-3-Methylglutaryl Coenzyme A Synthase, an Enzyme of Isopentenyl Diphosphate Biosynthesis , 2002, Journal of bacteriology.
[75] H. Miziorko,et al. The Structure of a Binary Complex between a Mammalian Mevalonate Kinase and ATP , 2002, The Journal of Biological Chemistry.
[76] J. Urbina. Specific treatment of Chagas disease: current status and new developments , 2001, Current opinion in infectious diseases.
[77] Joseph L. Goldstein,et al. The Cholesterol Quartet , 2001, Science.
[78] J. Deisenhofer,et al. Structural Mechanism for Statin Inhibition of HMG-CoA Reductase , 2001, Science.
[79] H. Miziorko,et al. Investigation of Invariant Serine/Threonine Residues in Mevalonate Kinase , 2001, The Journal of Biological Chemistry.
[80] B. Clantin,et al. Crystal structure of isopentenyl diphosphate:dimethylallyl diphosphate isomerase , 2001, The EMBO journal.
[81] T. Porter,et al. Inhibition of human squalene monooxygenase by tellurium compounds: evidence of interaction with vicinal sulfhydryls. , 2001, Journal of lipid research.
[82] J. Deisenhofer,et al. The structure of the catalytic portion of human HMG-CoA reductase. , 2000, Biochimica et biophysica acta.
[83] S. Krisans,et al. Peroxisomal protein targeting and identification of peroxisomal targeting signals in cholesterol biosynthetic enzymes. , 2000, Biochimica et biophysica acta.
[84] S. Krisans,et al. Identification of peroxisomal targeting signals in cholesterol biosynthetic enzymes. AA-CoA thiolase, hmg-coa synthase, MPPD, and FPP synthase. , 2000, Journal of lipid research.
[85] H. Miziorko,et al. 3-Hydroxy-3-methylglutaryl-CoA synthase: participation of invariant acidic residues in formation of the acetyl-S-enzyme reaction intermediate. , 2000, Biochemistry.
[86] D. Danley,et al. Crystal Structure of Human Squalene Synthase , 2000, The Journal of Biological Chemistry.
[87] Y. Modis,et al. Crystallographic analysis of the reaction pathway of Zoogloea ramigera biosynthetic thiolase. , 2000, Journal of molecular biology.
[88] I. Abe,et al. Potent and selective inhibition of squalene epoxidase by synthetic galloyl esters. , 2000, Biochemical and biophysical research communications.
[89] J. Deisenhofer,et al. Crystal structure of the catalytic portion of human HMG‐CoA reductase: insights into regulation of activity and catalysis , 2000, The EMBO journal.
[90] Y. Modis,et al. A biosynthetic thiolase in complex with a reaction intermediate: the crystal structure provides new insights into the catalytic mechanism. , 1999, Structure.
[91] L. Tabernero,et al. Aminoethylcysteine can replace the function of the essential active site lysine of Pseudomonas mevalonii 3-hydroxy-3-methylglutaryl coenzyme A reductase. , 1999, Biochemistry.
[92] L. Tabernero,et al. Substrate-induced closure of the flap domain in the ternary complex structures provides insights into the mechanism of catalysis by 3-hydroxy-3-methylglutaryl-CoA reductase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[93] K. Gibson,et al. Characterization of phosphomevalonate kinase: chromosomal localization, regulation, and subcellular targeting. , 1999, Journal of lipid research.
[94] F. Hegardt. Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: a control enzyme in ketogenesis. , 1999, The Biochemical journal.
[95] G. Schulz,et al. The structure of the membrane protein squalene-hopene cyclase at 2.0 A resolution. , 1999, Journal of molecular biology.
[96] G. Ness,et al. Dietary cholesterol regulates hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in rats primarily at the level of translation. , 1998, Archives of biochemistry and biophysics.
[97] W. L. Jorgensen,et al. Computational Investigations of Carbenium Ion Reactions Relevant to Sterol Biosynthesis , 1997 .
[98] T. Hashimoto,et al. Medium Chain 3-Ketoacyl-Coenzyme A Thiolase Deficiency: A New Disorder of Mitochondrial Fatty Acid β-Oxidation , 1997, Pediatric Research.
[99] H. Miziorko,et al. Identification of Catalytic Residues in Human Mevalonate Kinase* , 1997, The Journal of Biological Chemistry.
[100] E. Waelkens,et al. Substrate Specificities of 3-Oxoacyl-CoA Thiolase A and Sterol Carrier Protein 2/3-Oxoacyl-CoA Thiolase Purified from Normal Rat Liver Peroxisomes , 1997, Journal of Biological Chemistry.
[101] G. Ness,et al. Translational regulation of hepatic HMG-CoA reductase by dietary cholesterol. , 1997, Biochemical and biophysical research communications.
[102] H. Miziorko,et al. Identification and Functional Characterization of an Active-site Lysine in Mevalonate Kinase* , 1997, The Journal of Biological Chemistry.
[103] J C Sacchettini,et al. Regulation of product chain length by isoprenyl diphosphate synthases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[104] G. Smith,et al. Inhibition of squalene synthase of rat liver by novel 3' substituted quinuclidines. , 1996, Biochemical pharmacology.
[105] G. Ness,et al. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver. , 1996, Archives of biochemistry and biophysics.
[106] J. Rine,et al. The biology of HMG-CoA reductase: the pros of contra-regulation. , 1996, Trends in biochemical sciences.
[107] J. Sakakibara,et al. Purification and characterization of recombinant squalene epoxidase. , 1995, Journal of lipid research.
[108] G. Ness,et al. Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 alpha hydroxylase. , 1994, Archives of biochemistry and biophysics.
[109] P. Edwards,et al. Farnesyl-diphosphate synthase is localized in peroxisomes. , 1994, The Journal of biological chemistry.
[110] V. Rodwell,et al. Catalysis by Syrian hamster 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Proposed roles of histidine 865, glutamate 558, and aspartate 766. , 1994, The Journal of biological chemistry.
[111] C. Poulter,et al. Yeast farnesyl-diphosphate synthase: site-directed mutagenesis of residues in highly conserved prenyltransferase domains I and II. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[112] G. Prestwich,et al. ENZYMATIC CYCLIZATION OF SQUALENE AND OXIDOSQUALENE TO STEROLS AND TRITERPENES , 1993 .
[113] H. Miziorko,et al. Avian 3-hydroxy-3-methylglutaryl-CoA synthase. Characterization of a recombinant cholesterogenic isozyme and demonstration of the requirement for a sulfhydryl functionality in formation of the acetyl-enzyme reaction intermediate. , 1993, The Journal of biological chemistry.
[114] P. Evans,et al. Site-directed mutagenesis identifies catalytic residues in the active site of Escherichia coli phosphofructokinase. , 1992, Biochemistry.
[115] V. Rodwell,et al. Identification of the catalytically important histidine of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. , 1992, The Journal of biological chemistry.
[116] Y. Yamori,et al. Liver mevalonate 5-pyrophosphate decarboxylase is responsible for reduced serum cholesterol in stroke-prone spontaneously hypertensive rat. , 1992, The Journal of biological chemistry.
[117] N. Ryder,et al. Terbinafine: Mode of action and properties of the squalene epoxidase inhibition , 1992, The British journal of dermatology.
[118] Y. Sawasaki,et al. Hypolipidemic effects of NB-598 in dogs. , 1991, Atherosclerosis.
[119] V. Rodwell,et al. Identification of the principal catalytically important acidic residue of 3-hydroxy-3-methylglutaryl coenzyme A reductase. , 1990, The Journal of biological chemistry.
[120] C. Poulter,et al. Hydrogen exchange during the enzyme-catalyzed isomerization of isopentenyl diphosphate and dimethylallyl diphosphate , 1990 .
[121] Y. Iwasawa,et al. NB-598: a potent competitive inhibitor of squalene epoxidase. , 1990, The Journal of biological chemistry.
[122] C. Poulter. Biosynthesis of non-head-to-tail terpenes. Formation of 1'-1 and 1'-3 linkages , 1990 .
[123] J. Goldstein,et al. Regulation of the mevalonate pathway , 1990, Nature.
[124] K. Svenson,et al. Identification of a zinc finger protein that binds to the sterol regulatory element. , 1989, Science.
[125] C. Walsh,et al. Mechanistic studies on beta-ketoacyl thiolase from Zoogloea ramigera: identification of the active-site nucleophile as Cys89, its mutation to Ser89, and kinetic and thermodynamic characterization of wild-type and mutant enzymes. , 1989, Biochemistry.
[126] T. Osborne,et al. Operator constitutive mutation of 3-hydroxy-3-methylglutaryl coenzyme A reductase promoter abolishes protein binding to sterol regulatory element. , 1988, The Journal of biological chemistry.
[127] P. Hartlage,et al. Mitochondrial acetoacetyl-CoA thiolase deficiency. , 1986, Biochemical medicine and metabolic biology.
[128] R. Abeles,et al. Mechanism of action of isopentenyl pyrophosphate isomerase: evidence for a carbonium ion intermediate. , 1986, Biochemistry.
[129] H. Brewer,et al. In vivo modulation of rat liver 3-hydroxy-3-methylglutaryl-coenzyme A reductase, reductase kinase, and reductase kinase kinase by mevalonolactone. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[130] E. E. Tamelen. BIOORGANIC CHARACTERIZATION AND MECHANISM OF THE 2,3-OXIDOSQUALENE → LANOSTEROL CONVERSION , 1983 .
[131] M. Brown,et al. Regulation of synthesis and degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by low density lipoprotein and 25-hydroxycholesterol in UT-1 cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[132] W. Cleland,et al. pH properties and chemical mechanism of action of 3-hydroxy-3-methylglutaryl coenzyme A reductase. , 1981, Biochemistry.
[133] C. Poulter,et al. Farnesyl pyrophosphate synthetase. Mechanistic studies of the 1′-4 coupling reaction in the terpene biosynthetic pathway [13] , 1979 .
[134] E. E. Tamelen,et al. Generation of the onocerin system by lanosterol 2,3-oxidosqualene cyclase - implications for the cyclization process , 1979 .
[135] M. Brown,et al. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. , 1978, The Journal of biological chemistry.
[136] M. Astruc,et al. Squalene epoxidase and oxidosqualene lanosterol-cyclase activities in cholesterogenic and non-cholesterogenic tissues. , 1977, Biochimica et biophysica acta.
[137] M. Lane,et al. 3-Hydroxy-3-methylgutaryl-CoA synthase. Participation of acetyl-S-enzyme and enzyme-S-hydroxymethylgutaryl-SCoA intermediates in the reaction. , 1977, The Journal of biological chemistry.
[138] E. E. Tamelen,et al. Overall mechanism of terpenoid terminal epoxide polycyclizations , 1977 .
[139] C. Ramachandran,et al. Decarboxylation of mevalonate pyrophosphate is one rate-limiting step in hepatic cholesterol synthesis in suckling and weaned rats. , 1976, Biochemical and biophysical research communications.
[140] M. Lane,et al. 3-Hydroxy-3-methylglutaryl coenzyme A synthase. Evidence for an acetyl-S-enzyme intermediate and identification of a cysteinyl sulfhydryl as the site of acetylation. , 1975, The Journal of biological chemistry.
[141] K. Bloch,et al. Solubilization and partial characterization of rat liver squalene epoxidase. , 1975, The Journal of biological chemistry.
[142] A. Grieder,et al. Cyclization of a terpenoid diene with preformed A-B-D rings and its significance for the mechanism of terpenoid terminal epoxide cyclizations , 1974 .
[143] W. Cleland,et al. Purification and mechanism of action of hog liver mevalonic kinase. , 1970, The Journal of biological chemistry.
[144] J. D. Willett,et al. On the mechanism of lanosterol biosynthesis from squalene 2,3-oxide. , 1967, Journal of the American Chemical Society.
[145] M. Schwartz,et al. Nonenzymic laboratory cyclization of squalene 2,3-oxide. , 1966, Journal of the American Chemical Society.
[146] E. Corey,et al. 2,3-oxidosqualene, an intermediate in the biological synthesis of sterols from squalene. , 1966, Journal of the American Chemical Society.
[147] K. Bloch,et al. THE ENZYMATIC CONVERSION OF MEVALONIC ACID TO SQUALENE , 1957 .
[148] D. Płochocka,et al. Farnesyl diphosphate synthase; regulation of product specificity. , 2005, Acta biochimica Polonica.
[149] A. Chugh,et al. Squalene epoxidase as hypocholesterolemic drug target revisited. , 2003, Progress in lipid research.
[150] M. Hedl,et al. 3-Hydroxy-3-methylglutaryl-CoA reductase. , 2000, Methods in enzymology.
[151] D. Strickland,et al. The mammalian low-density lipoprotein receptor family. , 1999, Annual review of nutrition.
[152] J. Trzăskos,et al. Effects of 15-oxa-32-vinyl-lanost-8-ene-3 beta,32 diol on the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase and low density lipoprotein receptor in rat liver. , 1998, Archives of biochemistry and biophysics.
[153] T. Hashimoto,et al. Characterization of N93S, I312T, and A333P missense mutations in two Japanese families with mitochondrial acetoacetyl‐CoA thiolase deficiency , 1998, Human mutation.
[154] A. Palotie,et al. Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency with the G1528C mutation: clinical presentation of thirteen patients. , 1997, The Journal of pediatrics.
[155] J. D. Karkas,et al. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[156] D. Gordon,et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.